Targeted therapeutic approaches in squamous cell vulvar cancer (VSCC): Case series and review of the literature.

Targeted therapeutic approaches in squamous cell vulvar cancer (VSCC): Case series and review of the literature. Oncol Res. 2020 Dec 11;: Authors: Woelber L, Mathey S, Prieske K, Kuerti S, Hillen C, Burandt E, Coym A, Mueller V, Schmalfeldt B, Jaeger A Abstract Therapeutic options in recurrent or metastasized VSCC not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 2013 - 2019 were retrospectively evaluated for targeted therapeutic approaches. Furthermore, a MEDLINE, EMBASE-, Web of Science-, Scopus- and OVID database search was performed using the terms: 'vulvar cancer' AND 'targeted therapy', 'erlotinib', 'EGFR', 'bevacizumab', 'VEGF', 'pembrolizumab or 'immunotherapy'. 12/291 patients (4.1%) with VSCC received at least one targeted therapy at our institution. Previously, one or more platinum-based chemotherapy was applied to all patients (median 3.5 previous lines (range 2-5). In the erlotinib subgroup 2/5 patients (40%) achieved stable disease (SD) while two patients (2/5, 40%) experienced partial response (PR). Treatment was given as monotherapy in 2nd/3rd line for a median of 3.4 months (range 2-6 months). Bevacizumab (n=9) was given as maintenance therapy after platinum-based first-line chemotherapy (9/9), best response was complete response (CR) (n=2/9 22.2%). Median duration of tr...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research